These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6330853)

  • 21. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.
    Moriniere BJ; van Loon FP; Rhodes PH; Klein-Zabban ML; Frank-Senat B; Herrington JE; Pallansch MA; Patriarca PA
    Lancet; 1993 Jun; 341(8860):1545-50. PubMed ID: 8099637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poliovirus antibody differentiation. Methods and application for strain specific diagnosis in complications after oral vaccination.
    Kuwert E; Höher PG; Thraenhart O
    Zentralbl Bakteriol Orig A; 1976 Apr; 234(3):407-12. PubMed ID: 180727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Use of the Vero transplantable cell line in a color test reaction for the quantitative determination of poliomyelitis virus-neutralizing antibodies].
    Karaseva IA; Boĭko VM
    Vopr Virusol; 1979; (5):562-3. PubMed ID: 228500
    [No Abstract]   [Full Text] [Related]  

  • 24. Persistence of poliovirus neutralizing antibodies eight years after immunization with live, attenuated-virus vaccine.
    Rousseau WE; Noble GR; Tegtmeier GE; Jordan MC; Chin TD
    N Engl J Med; 1973 Dec; 289(25):1357-9. PubMed ID: 4356637
    [No Abstract]   [Full Text] [Related]  

  • 25. A novel multiplex poliovirus binding inhibition assay applicable for large serosurveillance and vaccine studies, without the use of live poliovirus.
    Schepp RM; Berbers GA; Ferreira JA; Reimerink JH; van der Klis FR
    J Virol Methods; 2017 Mar; 241():15-23. PubMed ID: 27988324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum antibody to poliovirus in patients in a mental deficiency hospital, with particular reference to Down's syndrome.
    McKay E; Hems G; Massie A; Moffat MA; Phillips KM
    J Hyg (Lond); 1978 Aug; 81(1):25-30. PubMed ID: 211162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Investigation of poliovirus neutralizing antibody level in nurse students].
    Otatsume S; Kinebuchi H
    Kansenshogaku Zasshi; 1973 Aug; 47(8):275-82. PubMed ID: 4357905
    [No Abstract]   [Full Text] [Related]  

  • 28. Antibody persistence after primary immunization with trivalent oral poliovirus vaccine.
    Krugman RD; Hardy GE; Sellers C; Parkman PD; Witte JJ; Meyer BC; Meyer HM
    Pediatrics; 1977 Jul; 60(1):80-2. PubMed ID: 195265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of poliovirus neutralizing antibodies in young adult women.
    Mayer TR; Balfour HH
    JAMA; 1981 Sep; 246(11):1207-9. PubMed ID: 6267329
    [No Abstract]   [Full Text] [Related]  

  • 30. Peptide priming of a poliovirus neutralizing antibody response.
    Wimmer E; Emini EA; Jameson BA
    Rev Infect Dis; 1984; 6 Suppl 2():S505-9. PubMed ID: 6330847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses.
    Faden H; Modlin JF; Thoms ML; McBean AM; Ferdon MB; Ogra PL
    J Infect Dis; 1990 Dec; 162(6):1291-7. PubMed ID: 2172403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serosurvey for polio antibodies.
    Biberi-Moroeanu S; Munţiu A; Stoiculescu S
    Virologie; 1988; 39(4):241-5. PubMed ID: 2851206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reactivity of neutralizing antibodies with different specificities to H particles of poliovirus.
    Urasawa T; Urasawa S; Taniguchi K
    Microbiol Immunol; 1979; 23(7):651-7. PubMed ID: 228166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A "spot-infection technique" for titration and neutralization of poliovirus.
    Baba K; Kimoto T; Morita K
    Biken J; 1973 Jun; 16(2):75-80. PubMed ID: 4354120
    [No Abstract]   [Full Text] [Related]  

  • 35. Seroimmunity to poliomyelitis in hospital personnel.
    Tang RB; Wang HC; Lee SJ; Chang TK; Hwang B
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1984 Nov; 17(4):188-92. PubMed ID: 6099791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of antipoliovirus monoclonal antibodies as an improved safety test for oral live poliomyelitis vaccine.
    Horie H; Sato M; Doi Y; Hashizume S
    Vaccine; 1996 Jan; 14(1):35-41. PubMed ID: 8821647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hit-and-run neutralization of poliovirus.
    Brioen P; Rombaut B; Boeyé A
    J Gen Virol; 1985 Nov; 66 ( Pt 11)():2495-9. PubMed ID: 2997379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-lasting poliovirus-neutralizing antibodies among Argentinean population immunized with four or five oral polio vaccine doses 1 month to 19 years previously.
    Nates SV; Martinez LC; Barril PA; Ferreyra LJ; Giordano MO; Masachessi G; Isa MB
    Viral Immunol; 2007; 20(1):3-10. PubMed ID: 17425416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence for several unrelated neutralization epitopes of poliovirus, type 1, strain Mahoney, provided by neutralization tests and quantitative enzyme-linked immunosorbent assay (ELISA).
    Uhlig H; Rutter G; Dernick R
    J Gen Virol; 1983 Dec; 64 ( Pt 12)():2809-12. PubMed ID: 6198443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seroimmunity to polioviruses in an urban population of Italy.
    Volpi A; Ragona G; Biondi W; Rocchi G; Archetti I
    Bull World Health Organ; 1976; 54(3):275-8. PubMed ID: 191208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.